Hookipa and Gilead Enter into a Collaboration and License Agreement to Develop Immunotherapies Against HIV and Hepatitis B

in portfolio news

Hookipa Biotech AG (“Hookipa”), a clinical-stage biotech company pioneering an innovative class of active immunization
therapies for oncology and infectious diseases and Gilead Sciences, Inc., (“Gilead”), a
research-based biopharmaceutical company that discovers, develops and commercializes
innovative medicines in areas of unmet medical need, today announced that they have
entered into a research collaboration and license agreement that grants Gilead exclusive
rights to Hookipa’s TheraT® and Vaxwave® arenavirus vector-based immunization
technologies for two major chronic infectious disease indications, hepatitis B virus (HBV) and
human immunodeficiency virus (HIV).

Under the terms of the agreement, Gilead will provide an upfront payment of $10 million.
Additionally, Hookipa will be eligible to receive milestone payments based upon the
achievement of specified development, regulatory, and commercial milestones up to a total of
more than $400 million. Gilead will fund all research and development activities. Hookipa will
also be eligible to receive tiered royalties on net sales.

"Gilead, a world leader in innovative therapies against major viral diseases, is the ideal
partner for us to drive our pipeline development in this area for the benefit of patients in need.
This partnership is strong recognition of our unique immunization technology, and helps us
concentrate our own energy and resources on immuno-oncology,” commented Joern Aldag,
Chief Executive Officer of Hookipa. "The collaborative HIV and HBV programs nicely
complement our significant efforts in the infectious disease area with an exciting proprietary
prophylactic CMV vaccine.”

“Gilead is committed to advancing innovative approaches directed at functional cures against
HIV and HBV,” said Bill Lee, PhD, Executive Vice President of Research, Gilead. “We are
convinced that Hookipa’s unique therapeutic vaccine technology, which has demonstrated
excellent safety and immunogenicity in Phase 1 clinical studies, has strong potential to have
synergistic effect with other Gilead cure efforts in both of these diseases areas. Our ultimate
long-term goal is to eliminate the need for life-long antiviral therapy for millions of patients
around the world.”